

# Republic of Moldova

Population 2016

4.1 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.26 (0.24–0.27)	6.3 (5.9–6.7)
Mortality (HIV+TB only)	0.062 (0.046–0.08)	1.5 (1.1–2)
Incidence (includes HIV+TB)	4.1 (3.5–4.7)	101 (87–117)
Incidence (HIV+TB only)	0.37 (0.31–0.43)	9.2 (7.8–11)
Incidence (MDR/RR-TB)**	2.3 (1.9–2.6)	56 (47–65)

Estimated TB incidence by age and sex (thousands)*, 2016	Estimated TB incidence by age and sex (thousands)*, 2016		Total
	0-14 years	> 14 years	
Females	0.19 (0.16–0.22)	1 (0.86–1.2)	1.2 (1–1.4)
Males	0.21 (0.18–0.25)	2.7 (2.3–3.1)	2.9 (2.5–3.3)
Total	0.4 (0.34–0.46)	3.7 (3.1–4.3)	4.1 (3.5–4.7)

TB case notifications, 2016	
Total cases notified	4 134
Total new and relapse	3 571
- % tested with rapid diagnostics at time of diagnosis	51%
- % with known HIV status	94%
- % pulmonary	91%
- % bacteriologically confirmed among pulmonary	62%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2016	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.08 (0.07–0.09)

TB/HIV care in new and relapse TB patients, 2016	Number	(%)
Patients with known HIV-status who are HIV-positive	293	9%
- on antiretroviral therapy	193	66%

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			1 400 (1 300–1 400)
Estimated % of TB cases with MDR/RR-TB	26% (24–28)	56% (51–60)	
% notified tested for rifampicin resistance	58%	65%	2 491
MDR/RR-TB cases tested for resistance to second-line drugs			862
Laboratory-confirmed cases		MDR/RR-TB: 1 031, XDR-TB: 72	
Patients started on treatment ****		MDR/RR-TB: 1 037, XDR-TB: 65	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2015	80%	2 992
Previously treated cases, excluding relapse, registered in 2015	47%	217
HIV-positive TB cases registered in 2015	55%	227
MDR/RR-TB cases started on second-line treatment in 2014	50%	919
XDR-TB cases started on second-line treatment in 2014	33%	9

TB preventive treatment, 2016	
% of HIV-positive people (newly enrolled in care) on preventive treatment	0%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2017	
National TB budget (US\$ millions)	33
Funding source: 74% domestic, 18% international, 8% unfunded	

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


## Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016




Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded  
— Funded internationally  
— Funded domestically